Key Highlights
- Shares reached a record peak of $264.98 before climbing further to $268.69, representing a 3.70% daily increase
- Annual total return has reached an impressive 71% over the previous twelve months
- Guggenheim analysts elevated their price objective to $270 while maintaining a Buy recommendation, projecting Q2 revenue at $25.48 billion
- The company increased its quarterly payout to $1.34 per share from $1.30, continuing an unbroken 55-year streak of dividend growth
- Major institutional investors including Vanguard, State Street, and Norges Bank have significantly expanded their holdings
Shares of Johnson & Johnson reached unprecedented territory on Tuesday, initially peaking at $264.98 before advancing to $268.69 — representing a solid 3.70% increase for the session. This performance brings the pharmaceutical and medical device giant’s market capitalization to approximately $646.8 billion.
The stock has delivered exceptional returns of 71% throughout the past year, with its twelve-month low of $154.21 now a distant memory.
At present valuation levels, JNJ carries a price-to-earnings ratio of 31.02 and a PEG ratio of 2.58. The stock’s fifty-day moving average stands at $233.72, while the two-hundred-day moving average registers at $231.37 — both significantly below current trading levels.
Tuesday’s trading volume totaled 1.79 million shares, notably lighter than the average daily volume of 8.41 million. This type of low-volume upward movement often indicates methodical accumulation by long-term investors rather than speculative enthusiasm.
Wall Street Targets Being Surpassed
Guggenheim recently elevated its price objective to $270 while reaffirming a Buy recommendation. The investment firm anticipates J&J will report Q2 revenue of $25.48 billion alongside earnings per share of $2.87.
Leerink Partners upgraded the stock from Market Perform to Outperform in May, establishing a $265 price objective — a threshold JNJ has now exceeded. Wells Fargo maintains an Overweight rating with a $263 target price.
The average rating among 27 Wall Street analysts stands at “Moderate Buy” with a consensus price target of $257.13. With shares trading above this benchmark, the stock is outperforming Street expectations.
Bank of America and Barclays both maintain neutral/equal weight positions, with price objectives of $254 and $255 respectively.
Financial Performance and Shareholder Returns
The company’s latest quarterly results, announced April 14, revealed earnings per share of $2.70, surpassing the consensus estimate of $2.68. Revenue totaled $24.06 billion versus projections of $23.60 billion — reflecting a 9.9% year-over-year expansion.
The healthcare conglomerate also boosted its quarterly dividend to $1.34 from $1.30, distributed on June 9. This brings the annualized dividend to $5.36, yielding approximately 2.0% at current prices.
J&J has now increased its dividend payment for 55 straight years, maintaining its prestigious Dividend King status. The current payout ratio stands at 61.97%.
Fiscal year 2026 EPS guidance ranges from $11.45 to $11.65, with analyst consensus at $11.57.
Large-Scale Institutional Accumulation and Corporate Activity
Institutional ownership accounts for 69.55% of outstanding shares. Vanguard expanded its position by 3.73 million shares in Q4, bringing its total stake to 240.35 million shares. State Street increased holdings by 1.66 million to reach 133.87 million shares. Norges Bank initiated a substantial new position valued at approximately $6.92 billion.
Moran Wealth Management grew its investment by 15.4% during Q1, acquiring an additional 12,160 shares to total 90,903, worth $22.2 million.
Regarding insider transactions, EVP Kathryn Wengel divested 10,000 shares at $241.15 on June 11, trimming her position by 8.05%. She continues to hold 114,288 shares valued at approximately $27.6 million.
The company also disclosed plans for a $1 billion-plus capital investment in its Jacksonville, Florida facilities to enhance manufacturing capabilities for its Vision segment, including expanded production capacity for ACUVUE contact lenses.
Recent clinical data on IMAAVY (nipocalimab-aahu) for treating myasthenia gravis was showcased through 12 presentations at the European Academy of Neurology 2026 Congress.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
